LEADER 01435nam--2200421---450- 001 990001203770203316 005 20090601182108.0 010 $a84-8444-307-8 035 $a000120377 035 $aUSA01000120377 035 $a(ALEPH)000120377USA01 035 $a000120377 100 $a20031020d2002----km-y0enga50------ba 101 0 $aspa 102 $aES 105 $ay---z---001yy 200 1 $a<> problema de la parte general del derecho penal economico$eel actuar en nombre de otro$eanálisis del derecho penal español y cubano$fÁngel Linares Estrella 210 $aGranada$cEditorial Comares$d2002 215 $aXXIV, 409 p.$d25 cm 410 0$12001 454 1 $12001 461 1$1001------$12001 606 0 $aInfrazioni economiche e finanziarie$ySpagna 606 0 $aInfrazioni economiche e finanziarie$yCuba 676 $a346.46 700 1$aLINARES ESTRELLA,$bAngel$0556066 801 0$aIT$bsalbc$gISBD 912 $a990001203770203316 951 $aXXVI.1.D 79 (IG XXI 836)$b39467 G.$cXXVI.1.D 79 (IG XXI 836)$d00094066 959 $aBK 969 $aGIU 979 $aALINA$b10$c20031020$lUSA01$h1033 979 $aPATRY$b90$c20040406$lUSA01$h1726 979 $aIANNONE$b90$c20050506$lUSA01$h1404 979 $aIANNONE$b90$c20050506$lUSA01$h1407 979 $aRSIAV1$b90$c20090601$lUSA01$h1821 996 $aProblema de la parte general del derecho penal economico$9986142 997 $aUNISA LEADER 02975nam 2200529 450 001 9910583458603321 005 20230120002746.0 010 $a0-12-811962-4 010 $a0-12-811945-4 010 $a9780128119624$b(electronic bk.) 035 $a(CKB)4100000002574161 035 $a(MiAaPQ)EBC5313020 035 $a(EXLCZ)994100000002574161 100 $a20180316h20182018 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aEquitable access to high-cost pharmaceuticals /$fedited by Zaheer-ud-din Babar 210 1$aLondon :$cAcademic Press,$d2018. 210 4$d©2018 215 $a1 online resource (xviii, 221 pages) $cill 320 $aIncludes bibliographical references and index. 330 $aEquitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines. Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs Incorporates existing guidelines and recommendations by international organizations Compares and contrasts how different countries fund and police high-cost drug access Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing Reviews novel pharmaceuticals of current research interest 606 $aDrugs$xPrices 606 $aDrugs$xPrices$xLaw and legislation 606 $amedicinal product$9eng$2eurovoc 606 $apricing of medicines$9eng$2eurovoc 606 $apharmaceutical legislation$9eng$2eurovoc 606 $aresearch$9eng$2eurovoc 615 0$aDrugs$xPrices. 615 0$aDrugs$xPrices$xLaw and legislation. 615 7$amedicinal product 615 7$apricing of medicines 615 7$apharmaceutical legislation 615 7$aresearch 676 $a338.436151 686 $a28.24.20$2EP-CLASS 702 $aBabar$b Zaheer-ud-din 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910583458603321 996 $aEquitable access to high-cost pharmaceuticals$92127831 997 $aUNINA